NCT00133874

Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 520 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 9 Months
• Healthy volunteers: Not accepted

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

Detailed description

A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative, Phase III Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo.

Conditions

• Skin Infections, Bacterial

Interventions

Type	Name	Description
DRUG	SB-275833 ointment, 1%

Timeline

• Start date: 2005-04-01
• Primary completion: 2005-09-01
• Completion: 2005-09-01
• First posted: 2005-08-24
• Last updated: 2017-01-23

Locations

69 sites across 10 countries: Canada, Costa Rica, France, Germany, India, Mexico, Netherlands, Peru, Poland, South Africa